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Abstract Hydrogen sulfide (H2S) is an endogenous
mediator that contributes to many important physiological
processes including vasodilation and vascular smooth
muscle relaxation; in turn, preventing tissue damage and
reducing inflammation. Heme oxygenase (HO) enzymes, of
which HO-1 is inducible by harmful stimuli, were found to
regulate intestinal inflammation in experimental animal
models of colitis. We aimed to investigate the protective
effects of H2S against 2,4,6-trinitrobenzenesulfonic acid
(TNBS)-induced colitis in rats, and whether HO enzyme
system is involved in the H2S-induced colonic cytopro-
tection. Male Wistar rats were treated with TNBS to induce
colitis, and H2S donor (Lawesson’s reagent) was prepared
two times/day at different concentrations, and delivered per
os (from day 1 to day 3). Our results suggest that daily
treatment (2 times/day) with H2S donor, could significantly
decrease the extent of colonic inflammation compared to
vehicle treatment, and the most effective daily dose of H2S
donor against inflammation was 18.75 lM/kg/day. Per os
administration of H2S donor increased the colonic HO
enzyme activity; on the contrary, the protective effect of
H2S was abolished by the co-treatment with HO inhibitor.
Our findings suggest that H2S confers colonoprotection,
probably by modulation of anti-inflammatory parameters
and HO enzyme activity.
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Introduction
Inflammatory bowel disease (IBD) is a serious chronic
condition associated with severe pain, diarrhea, and
bleeding. The term IBD comprises several types of gas-
trointestinal inflammatory diseases, and the most common
forms are Crohn’s disease (CD) and ulcerative colitis (UC)
(Lane et al. 2017). Treatment of these diseases is consid-
ered a big challenge and is modestly effective, except in
mild cases. Several inflammatory mediators, cytokines, and
chemokines have been implicated in the pathogenesis of
colitis (Neurath 2014). One of these mediators is TNF-a
which was mostly exploited from a therapeutic standpoint,
using monoclonal antibodies directed against this cytokine
(Biancone et al. 2007). However, these therapies are
expensive and risky. The most commonly used medication
for the treatment of colitis is mesalamine (5-aminosalicylic
acid), which is effective in inducing remission in mild
cases (Williams et al. 2011). Mesalamine has anti-inflam-
matory and immunomodulatory effects. The mechanism of
action is based on the inhibition of pro-inflammatory fac-
tors and antigen presentation, and increased free radical
scavenging (Desreumaux and Ghosh 2006). Based on
previous observations that H2S donor can attenuate some
elements of inflammation (leukocyte adherence, edema
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formation, etc.) in several tissues, such as myocardium,
brain, gastric tissue and large intestine, and can accelerate
the healing of injured gastrointestinal (GI) tract (Flannigan
et al. 2013), we studied the possible function of this
gasotransmitter in a rat model of colitis. In 1982, it was
reported that H2S is produced in mammalian cells during L-
cysteine metabolism with the involvement of three main
enzymes: cystathionine c-lyase (CSE), cystathionine b-
synthase (CBS) and 3-mercaptopyruvate sulfur transferase
(3-MST) (Stipanuk and Beck 1982). Then in 1996, Abe and
Kimura (Abe and Kimura 1996) proposed H2S as an
intracellular messenger in mammals. A vast array of
studies provided compelling evidence that H2S is an
important mediator of numerous physiological and patho-
physiological processes (Szabo 2007; Szabo and
Papapetropoulos 2011; Coletta and Szabo 2013). H2S is
considered an important vasodilator and neuromodulator,
in addition to other exerted effects in the digestive system
(Fiorucci et al. 2006), including modifications in ileal
smooth muscle contractility (Teague et al. 2002), stimu-
lation of intestinal secretion (Schicho et al. 2006) and
reduction of colorectal distension-induced visceral pain
(Distrutti et al. 2006). Moreover, some recent studies also
addressed that H2S can exert anti-inflammatory actions
(Magierowski et al. 2015; Chen and Liu 2016) and enhance
gastric ulcer healing (Magierowski et al. 2015). Over the
past 2 years, numerous reports strongly displayed that H2S
plays a potent (Motta et al. 2015; Badiei et al. 2016), but
complex and poorly understood role in the inflammation of
the gastrointestinal tract. The latter compound is also
considered a strong reducing agent and may function as an
important redox controlling molecule (Kashiba et al. 2002).
Heme oxygenase-1 (HO-1) enzyme is an inducible
stress protein whose expression can be markedly aug-
mented in eukaryotes by a wide range of substances that
cause a transient change in the cellular redox state (Mot-
terlini et al. 2002). The up-regulation of HO-1 and
consequent overproduction of intracellular bilirubin are
associated with protection against acute and chronic
inflammation in dextran sodium sulfate-induced colitis
(Uddin et al. 2013). Previous studies conducted in our
laboratory, convincingly proved that 5-aminosalicylic acid
(5-ASA) can induce the heat shock protein (HO-1) and
equally up-regulate HO enzyme activity in the colon
(Horvath et al. 2008). We have also displayed supporting
evidence regarding the protective role of HO-1, by apply-
ing subcutaneous heme administration (30 lmol/kg/day),
increased colonic HO-1 protein expression and enzyme
activity, along with a decrease in colonic damage and
myeloperoxidase (MPO) activity (Varga et al. 2007).
In the last few years, H2S-donor molecules and their
drug hybrids have drawn increasing interest, due to their
therapeutic potentials in inflammation-based pathologies
(Sparatore et al. 2011). Moreover, the anti-inflammatory
role of H2S in the context of colitis was markedly trans-
lated by an H2S-releasing derivative of mesalamine in
experimental colitis (Triantafillidis et al. 2014).
Therefore, the present study was performed to delineate
the possible role of H2S in experimental colitis, by
assessing the dose–response relationship of exogenously
administrated H2S donor in a rat model of colitis. We also
examined several potential mechanisms through which H2S
can modulate inflammation and contributes in resolving of
colitis, focusing on heme oxygenase enzyme. We hypoth-
esized that H2S-mediated colonoprotection against TNBS-
induced colitis in rats is due to the upregulation of the HO-
1 enzyme.
Methods
Experimental design
All manipulations were performed in accordance with the
standards of the European Community guidelines on the
care and use of laboratory animals, in addition to the
approval by the Institutional Ethics Committee (XX./4799/
2015) at the University of Szeged.
Male Wistar rats weighing (200–400 g) were purchased
from Toxicoop Ltd. (Dunakeszi, Hungary) and housed in a
room with acclimatized temperature, under 12-h day/night
cycles with free access to food and water. Animals were
divided randomly into five separate groups; (1) control (no
treatment); (2) 2,4,6-trinitrobenzenesulfonic acid treated
group (TNBS); (3) ethanol (EtOH) group, to observe the
effect of the solvent of TNBS; (4) colitis group treated with
various doses of Lawesson’s reagent as H2S donor
(TNBS?H2S), and (5) colitis group treated with sul-
fasalazine (SASP) as a positive control (TNBS?SASP).
Colitis was induced in all rat groups using TNBS, except
the control and EtOH group. Before intracolonic (i.c.)
administration of TNBS, rats were exposed for 18 h fast-
ing. Rats were anesthetized with diethyl-ether, then
prepared TNBS (10 mg/ml in 250 ml of 50% ethanol) was
administered via a disposable plastic catheter inserted 8 cm
deep into the colon from the anus (Szalai et al. 2014).
Immediately after TNBS administration, the (TNBS?H2S)
group was treated per os (twice/day) with various con-
centrations (600; 300; 150; 75; 37.5; 18.75; 9.3 lM/
kg/day) of the H2S donor from day 1 to day 3 (Lawesson’s
reagent).
The selection of doses for TNBS administration and
SASP was based on a previous experience with these drugs
(Varga et al. 2007). However, rats in group (TNBS?SASP)
received sulfasalazine (2 9 25 mg/kg) as a positive
control.
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HO-1 inhibition
To delineate the endogenous role of heme oxygenase in
inflammatory response, it was necessary to conduct another
series of experiments, in which tin-protoporphyrin (SnPP)
was administered in parallel with H2S
(TNBS?SnPP?H2S) or alone (SnPP) to inhibit the activity
of HO. Rats were injected subcutaneously with SnPP on a
daily basis, with a dose of (30 lmol/kg/day), and then they
were killed on day 3 after induction of colitis.
Damage score and lesion measurement
The extent of macroscopically apparent inflammation,
ulceration, and tissue disruption were determined in a
randomized manner from the colored images, using pro-
prietary computerized planimetry software developed in
our laboratory (Stat_2_1_1), based on planimetria. The
area of macroscopically visible mucosal involvement was
calculated and expressed as percentage (%) of the total
colonic segment area under study.
Myeloperoxidase (MPO) activity
Colonic inflammation was also assessed by the measure-
ment of MPO activity, using a modified method that was
previously described by Bradley et al. (Bradley et al.
1982). MPO is an enzyme found primarily in the azur-
ophilic granules of neutrophils, and has been used
extensively as a quantitative index of granulocytes
infiltration.
Longitudinal strips of segmented colon measuring 8 cm
were weighed and homogenized (Ultra-Turrax T25 IKA-
Labortechnik, 13.500 rev/min, twice for 30 s; 250 mg
colon/mL buffer) in ice-cold phosphate buffer (50 mM, pH
6.0), containing 0.5% hexadecyltrimethylammonium-bro-
mide. Prepared homogenates were freeze-thawed three
times and then centrifuged at 10,0009g for 15 min at 4 C.
A 12 ll aliquot of the supernatant was then mixed with 280
ll phosphate buffer (50 mM, pH 6.0) containing
(0.167 mg/ml) O-adenosine di hydrochloride (Sigma-
Aldrich), and then a 10 ll of 0.03% of hydrogen peroxide
was used to start the reaction, after which it was assayed
spectrophotometrically (Benchmark Microplate Reader,
Bio-Rad Labs, Hercules, CA, USA) at 490 nm after
shaking for 90 s. MPO activity was expressed as mU/mg
protein (Szalai et al. 2014).
Tumor necrosis factor-a (TNF-a) levels in colon
tissue
Tissue samples from the colon were thawed, weighed and
homogenized (Ultra-Turrax T25, 2 9 30 s on ice; 250 mg
tissue/ml buffer), using a modified Greenburg buffer
(300 mmol/l NaCl, 15 mmol/l Tris, 2 mmol/l MgCl2,
2 mmol/l Triton X-100, 20 ng/ml pepstatin A, 20 ng/ml
leupeptin, 20 ng/ml aprotinin; pH 7.4). Tissue homo-
genates were lysed for 30 min on ice and then centrifuged
twice (10 min, 14,0009g). The aliquots of the supernatants
were stored at -20 C for further use.
The TNF-a levels were determined by quantitative
TNF-a solid-phase enzyme linked immuno-sorbent assay
(Delisa and DeLateur 1983). Samples were measured
spectrophotometrically at 450 nm, after which they were
diluted with the buffer included in the assay kit (Hycult
Biotechnology b.v. 5405 Uden, The Netherlands). The
assay had a range of 0–2000 pg/ml with a minimum
detection level of 10 pg/ml of TNF-a. The TNF-a values
were expressed as pg/mg protein (Horvath et al. 2008).
Heme oxygenase (HO) enzyme activity
Heme oxygenase activity was assessed by measuring
bilirubin formation, using a slightly modified method
described by Tenhunen et al. (1968). The colon segment
was homogenized (Ultra-Turrax T25; 13,500/s; twice for
30 s) in ice-cold 10 mM N-[2-hydroxyethyl] piperazine-
N0-[2-ethanesulfonic acid] (HEPES, Sigma-Aldrich),
32 mM sucrose (Sigma-Aldrich), 1 mM dithiothreitol
(DTT, Sigma-Aldrich), 0.1 mM EDTA, 10 lg/ml soybean
trypsin inhibitor (Sigma-Aldrich), 10 lg/ml leupeptin
(Sigma-Aldrich), and 2 lg/ml aprotinin (Sigma-Aldrich),
at pH 7.4. The supernatant was harvested after centrifu-
gation for (30 min at 20,000 g and 4 C). Incubation was
carried out in dark at 37 C for 60 min with a 1.5-ml final
volume reaction mixture, containing: 2 mM glucose
6-phosphate (Sigma-Aldrich), 0.14 U/ml glucose 6-phos-
phate dehydrogenase (Sigma-Aldrich), 15 lM heme,
150 lM b-nicotinamide adenine dinucleotide phosphate
(b-NADPH, Sigma-Aldrich), 120 lg/ml rat liver cytosol as
a source of biliverdin reductase, 2 mM MgCl2, 100 mM
potassium phosphate buffer, and 150 ll of supernatant. The
reaction was stopped by placing the samples on ice. The
level of bilirubin formed was calculated from the differ-
ence between optical densities obtained at 460 and 530 nm.
One unit of heme oxygenase activity was defined as the
amount of bilirubin produced (nmol/h/mg protein) (Szalai
et al. 2014).
HO-1 expression in colon tissue
Homogenization of colonic tissue segments was performed
in ice-cold phosphate buffer (1, 37 M NaCl; 27 mM KCl;
80 mM Na2HPO4; 20 mM KH2PO4). Homogenates were
centrifuged for 20 min at 3000 rpm and 4 C. Aliquots
from supernatants were stored at -20 C for further use.
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The level of HO-1 expression was determined with quan-
titative enzyme linked immuno sorbent assay (Delisa and
deLateur), using rat HO-1-specific ELISA kit (numbered
201-11-0677) according to manufacturer’s protocol
(SunRed Biological Company). The HO-1 expression level
was expressed as ng protein/ml.
CBS and CSE western blot
Frozen colon tissues were powdered in liquid nitrogen by
using a porcelain mortar and pestle, and the powder was
suspended in lysis buffer (100 mM sodium phosphate, pH
7.4, containing 0.2% Triton X-100, 1 mM b-mercap-
toethanol, and 1% protease inhibitor cocktail (Sigma),
25 lg/ml phenylmethylsulfonyl fluoride, 10 lg/ml leu-
peptin, 20 lg/ml aprotinin), and incubated on ice for
30 min followed by centrifugation at 14.000g for 10 min at
4 C. The protein concentration in tissue extracts was
determined by using the Bradford assay and bovine serum
albumin as a standard. Proteins were resolved on 10%
sodium dodecylsulfate (SDS)-polyacrylamide gels and
transferred to nitrocellulose membranes. Blots were probed
with polyclonal anti-CBS or anti-CSE rabbit antibodies
(1:1000, Abcam). Secondary anti-rabbit antibodies conju-
gated with horseradish peroxidase. Signals were developed
by using an enhanced chemiluminescence system
(ECL ? Plus, Amersham Pharmacia Biotech., Bucking-
hamshire, UK) and exposed to Hyperfilm. Films were
analysed by using the ImageQuant Software (Amersham
Pharmacia Biotech., Buckinghamshire, UK) after scanning
with GelAnalyst 3.01 Software (Iconix, Toronto, Canada).
Measurement of CBS, CSE activity
The same sample homogenates as used for western blot
were used for CBS and CSE double-antibody sandwich
Elisa (Sunredbio, Shanghai, China). Enzyme activity in
colon samples was measured according to the manufac-
turer’s instructions. Results are expressed as ng/ml.
Protein determination
Using a commercial protein assay kit (Bio Rad, Hungary),
aliquots of 20 ll were taken from the diluted samples (259
or 509 with distilled water) and mixed with 980 ll dis-
tilled water. A 200 ll volume of Bradford reagent was
added to each sample. After mixing, followed by 10 min of
incubation, samples were assayed spectrophotometrically
at 595 nm. Protein level was expressed as mg protein/ml.
Statistical analysis
All data are presented as mean ± SEM. Statistical com-
parisons were performed using Student’s two-tailed
unpaired t test or Anova test. Differences were considered
when the p values were less than 0.05.
Results
Effect of H2S on the extent of colon lesion
Treatment with TNBS and its solvent EtOH also caused
obvious colonic mucosal injury compared with the
untreated healthy control, but EtOH caused less serious
lesions than TNBS (24.12 ± 3.33 vs. 39.39 ± 4.18%).
Release of H2S from Lawesson’s reagent caused protection
in the colon with 2 most effective concentrations: 37.5 lM/
kg (33.28 ± 4.68%) and 18.75 lM/kg (27.39 ± 1.54%),
compared to the control group. Daily dose of 18.75 lM/kg
of H2S donor was used in further experiments and
measurements.
The extent of colon inflammation was significantly
decreased in the positive control group (TNBS?SASP), the
decreasing was 8%. The area of macroscopically visible
mucosal damage was expressed as the percentage of the
total colonic segmented area (Fig. 1).
Effect of H2S on MPO activity in the colon
H2S donor caused a reduction in the TNBS-elevated MPO
levels (32.99 ± 6.2 mU/mg protein) in the colonic tissue
of rats. Significantly reduced MPO activity was observed in
150 lM/kg/day (17.13 ± 5.16 mU/mg protein), 75 lM/
kg/day (16.28 ± 5.24 mU/mg protein), 37.5 lM/kg/day
(16.12 ± 4.36 mU/mg protein) and 18.75 lM/kg/day
(19.07 ± 3.5 mU/mg protein) daily doses of H2S donor,
and after 50 mg/kg/day SASP treatment (15.49 ± 4 mU/
mg protein) as shown in Fig. 2.
Effect of H2S on TNF-a level in the colon
Colonic levels of TNF-a were measured in the animal
groups treated with the most effective H2S donor dose
(18.75 lM/kg), and with the (9.3 lM/kg) dose that was
ineffective against macroscopic colon lesions. Analo-
gously, in the positive control (TNBS ? SASP) group we
observed almost fivefold reduction in the colonic TNF-a
levels (from 531.67 ± 31.9 to 105.78 ± 17.7 pg/mg pro-
tein) and in the 18.75 lM/kg H2S donor dose group, the
decreasing was even more explicit (from 531.67 ± 31.9 to
89.95 ± 9.42 pg/mg protein) (Fig. 3).
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HO-1: expression and activity in the colon
Per os administration (twice/day) of H2S donor at a dose of
18.75 lM/kg, from the first day of TNBS treatment to the
end of the experimental period (day 3), caused a significant
enhancement in the colonic HO-1 enzyme expression
(from 0.26 ± 0.02 to 0.35 ± 0.04 ng/ml), compared to the
positive control group (0.32 ± 0.04 ng/ml). On the con-
trary, twice-daily administration of 9.3 lM/kg of H2S
donor was insufficient to increase the HO-1 expression
level (0.24 ± 0.03 ng/ml) (Fig. 4a).
The total HO activity in the colon was significantly
increased to (1.03 ± 0.05 nmol bilirubin/h/mg protein) and
(0.97 ± 0.05 nmol bilirubin/h/mg protein) in sulfasalazine
(TNBS?SASP) and 18.75 lM/kg dose of H2S donor
treated groups, respectively, compared to the TNBS group
(0.81 ± 0.06 nmol bilirubin/h/mg protein). However, a
non-significant increase (0.93 ± 0.09 nmol bilirubin/h/mg
protein) in the enzyme activity was shown in response to
the 9.3 lM/kg dose of H2S donor-treated group. The data
are shown in Fig. 4b.
Extent of colon lesion in the presence of HO
inhibitor (SnPP)
In order to investigate whether the protective effect of H2S
against colitis could be modulated by direct attenuation of
heme-oxygenase, the effect of concurrent subcutaneous
(s.c.) administration of the HO-1 inhibitor (SnPP) at a dose
of 30 lmol/kg/day on colonic inflammatory damage was
evaluated. The administration of this dose of SnPP with the
commencement of TNBS treatment resulted in reduction of
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Fig. 1 a Effects of different H2S treatment doses on the extent of
colon lesion (expressed in %). Results are shown as mean ± SEM;
(n = 4–11 animals/group). Statistical significance: *p\ 0.05 relative
to the TNBS group (Student’s two-tailed unpaired t test). Control
(untreated group); EtOH (ethanol, the solvent of TNBS); TNBS
(2,4,6-trinitrobenzenesulfonic acid treated group); TNBS?SASP
(2,4,6-trinitrobenzenesulfonic acid?sulfasalazine-treated group);
TNBS (2,4,6-trinitrobenzenesulfonic acid) ?600, 300, 150, 75,
37.5, 18.75, 9.3 lM/kg dose H2S donor treated groups. b Control
group’s healthy colon. c Representative picture of TNBS induced
ulceration. d EtOH induced injury. e TNBS administered colon,
treated with SASP. f TNBS, treated with 37.5 lM/kg H2S donor.
g TNBS, treated with 18.75 lM/kg H2S donor
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the protective activity of H2S on colitis, compared to H2S
effect alone (18.75 lM/kg). Indeed, H2S induced colono-
protection, with a 14% decrease in inflammation compared
to TNBS alone. Administration of SnPP alone did not
cause any significant increase in the area of colonic
inflammatory damage. The latter results are represented in
Fig. 5.
CSE, CBS expression and activity
To investigate whether CSE and CBS expressions are
altered, we compared the effect of TNBS solvents (ethanol)
and TNBS dissolved in ethanol (EtOH) to that of control on
CSE and CBS expressions and activity. Our results showed
that the expressions of both enzymes were significantly
decreased in both treated groups compared to control. In
case of CSE expression, the EtOH group was decreased to
(7320.431 ± 506.3505 mm2), while the TNBS group was
(5835.478 ± 497.3444 mm2) compared to control group
(9370.774 ± 752.2172 mm2) (Fig. 6a). CBS expressions
are also significantly changed in the EtOH group to
(2022.674 ± 137.9499 mm2) and TNBS to (1602.918 ±
127.724 mm2) from control group (2917.169 ±
123.9031 mm2) (Fig. 6b).
When measuring CSE and CBS activities in TNBS-in-
duced colitis colon samples, both treated groups showed a
decrease in the activities of the two tested enzymes, but our
results showed no statistical significance (Fig. 7a, b).
Discussion
Hydrogen sulfide (H2S) was recently reported as a novel
gasotransmitter, and its biological function has attracted
growing interest in recent years (Wallace and Wang 2015),
and sulfide quinone reductase (SQR) is considered as a key
enzyme for oxidation of H2S (Flannigan et al. 2013).
Mucosal ulcerations processes are accompanied by signif-
icant decrease in sulfide quinone reductase expression,
promoting a significant increase in H2S concentration at
sites of injury which is important for healing (Flannigan
et al. 2013). The 3 enzyme systems: cystathionine c-lyase
(CSE), cystathionine b-synthase (CBS), and 3-mercap-
topyruvate sulfurtransferase (3MST) are responsible for the
primarily synthesis of H2S at the site of mucosal damage
(Flannigan et al. 2013). Rats with a diet-induced deficiency
of B vitamins have reduced capacity to synthesize H2S (via
CSE and CBS, which require vitamin B6 for their activity),
exhibiting significant enhanced inflammatory responses,
including accumulation of leukocytes at the site of affected
tissues (Flannigan et al. 2014). Accumulating evidence
revealed that H2S plays pivotal roles in inflammatory
bowel diseases, and targets implicated in H2S colonopro-
tection are multiple, involving the activation of ATP
sensitive potassium channels, elevation of cAMP, scav-
enging peroxynitrite, increase mucosal blood flow, and
reduction of leukocyte adhesion/infiltration (Zhang et al.
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Fig. 3 Changes in colon tumor necrosis factor-a (TNF-a) levels
(expressed in pg/mg protein) among different treated groups. Results
are shown as mean ± SEM; (n = 4–8 animals/group). Statistical
significance: *p\ 0.05 relative to the TNBS group (One Way
ANOVA,Tukey post hoc test). TNBS (animal group treated with
2,4,6-trinitrobenzenesulfonic acid); TNBS?SASP (animal group
treated with 2,4,6-trinitrobenzenesulfonic acid and sulfasalazine);
TNBS?18.75 lM/kg H2S (animal group treated with 2,4,6-trini-
trobenzenesulfonic acid and 18.75 lM/kg dose of Hydrogen Sulfide
donor); and TNBS?9.3 lM/kg H2S (animal group treated with 2,4,6-
trinitrobenzenesulfonic acid and 9.3 lM/kg dose of hydrogen sulfide
donor)
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Fig. 4 Changes in heme oxygenase-1 (HO-1) enzyme expression
(expressed in ng/ml) (a) and HO-1 activity (expressed in nmol
bilirubin/h/mg protein) (b) in the colon of several treated animal
groups. Data are shown as mean ± SEM; (n = 5–8 animals/group).
Statistical significance: *p\ 0.05 relative to the TNBS group
(Student’s two-tailed unpaired t test). TNBS (animal group treated
with 2,4,6-trinitrobenzenesulfonic acid); TNBS?SASP (animal group
treated with 2,4,6-trinitrobenzenesulfonic acid and sulfasalazine);
TNBS?18.75 lM/kg H2S (animal group treated with 2,4,6-trini-
trobenzenesulfonic acid and 18.75 lM/kg dose of hydrogen sulfide
donor); and TNBS?9.3 lM/kg H2S (animal group treated with 2,4,6-
trinitrobenzenesulfonic acid and 9.3 lM/kg dose of hydrogen sulfide
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Fig. 5 a Changes in the extent of colonic lesion (expressed in %) in
different treated animal groups, and using the heme oxygenase (HO)
inhibitor (SnPP). Data are shown as mean ± SEM; (n = 6 ani-
mals/group). Statistical significance: *p\ 0.05 relative to the TNBS
group (Student’s two-tailed unpaired t test). TNBS (animal group
treated with 2,4,6-trinitrobenzenesulfonic acid); TNBS?18.75 lM/kg
H2S (animal group treated 2,4,6-trinitrobenzenesulfonic acid and
18.75 lM/kg dose of hydrogen sulfide donor); TNBS?18.75 lM/kg
H2S ? SnPP (animal group treated with 2,4,6-trinitrobenzenesulfonic
acid, 18.75 lM/kg dose of Hydrogen Sulfide donor and Tin-proto-
porphyrin); SnPP (animal group treated with Tin-protoporphyrin
alone). b TNBS induced ulceration. c TNBS treated with 18.75 lM/
kg H2S donor. d TNBS treated with 18.75 lM/kg H2S donor and
SnPP
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2007; Lo Faro et al. 2014). H2S can also protect intestine
from ischaemia–reperfusion injury in rats (Liu et al. 2009),
shown to promote neutrophil phagocytosis of bacteria, and
drive differentiation of macrophages to the proresolution
‘‘M2’’ phenotype (Dufton et al. 2012), and trigger gastric
and duodenal secretion of bicarbonate, which neutralizes
gastric acid, thereby limiting the damaging effects during
inflammation (Blackler et al. 2014). The beneficial effect of
H2S in the context of colitis was suggested recently by a
marked decrease in the level of anti-inflammatory cytoki-
nes like TNF-a and interferon-c, possibly a consequence of
the reported ability of H2S to inhibit activation of nuclear
transcription factor (Zhang et al. 2008), and our results line
up with these observations, showing that colonic TNF-a
was decreased in the H2S-treated group. Inhibition of
cyclooxygenase (COX) activity by NSAIDs does not
appear to be the primary driver of injury during inflam-
mation; rather, it is the secretion of the NSAID into bile
(enterohepatic circulation of the NSAID), and the irritant
properties of NSAID-containing bile, and the microbiota of
the intestine that play the key roles in producing this
damage (Wallace 2012), while treatment with H2S donor
did trigger a significant increase in COX-2 expression and
prostaglandin E2 synthesis by intestinal tissue, contributing
in the protective effects against NSAID enteropathy
(Blackler et al. 2015). Mesalamine (5-aminosalicylic acid)
is a weak anti-inflammatory drug and not considered as an
NSAID, having no inhibitory effects on COX activity
(Fiorucci et al. 2007). Similarly, in the present study, we
observed that exogenous H2S donor could resolve the
inflammation in TNBS induced colonic ulcers in rats,
especially the H2S releasing derivatives of nonsteroidal
anti-inflammatory drugs (NSAIDs) have been shown to be
more effective than the parent NSAIDs, causing markedly
less gastric injury (Wallace et al. 2007). According to
previous studies, it was convincingly clear that agents
containing sulfhydryl groups were protective in a number
of models against gastrointestinal diseases (Oyagi et al.
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Fig. 6 Changes in CSE (a) and CBS (b) expressions in rat colitis
induced by TNBS. Data are shown as mean ± SEM; (n = 4–7
animals/group). Statistical significance: *p\ 0.05 relative to the
control (Student’s two-tailed unpaired t-test or ANOVA, Tukey post
hoc test). Control (animals were not treated); EtOH (animals were
treated only with ethanol (EtOH), the solvent of TNBS); TNBS group
(animals treated with TNBS dissolved in EtOH)
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Fig. 7 Changes in the H2S-generating CSE (a) and CBS enzymes’
(b) activities in treated groups. Data are shown as mean ± SEM;
(n = 4–7 animals/group). Statistical significance: *p\ 0.05 relative
to the control (Student’s two-tailed unpaired t test). Control (animals
were not treated); EtOH (animals were treated only with ethanol
(EtOH), the solvent of TNBS); TNBS group (animals treated with
TNBS dissolved in EtOH)
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2010). In a DSS-induced colitis model, treatment with
garlic oil as an H2S donor could significantly attenuate the
severity of colitis and reduces the expression level and
activity of several key inflammatory markers, such as TNF-
a and MPO (Balaha et al. 2016), and according to Wallace
et al. (2009), the intracolonic administration of NaHS as an
H2S donor can protect colonic mucosa in rats; however, the
detailed mechanism of this protection is not entirely clear.
Studies on H2S-NSAIDs like (ATB-346) were found to
produce negligible GI damage (Blackler et al. 2012).
Moreover, animals treated with ATB-429 (H2S-derivative
of mesalamine), but not the mesalamine itself could
markedly reduce tissue levels of granulocytes (Fiorucci
et al. 2007), and significantly reduced tissue expression of a
number of pro-inflammatory cytokines (IL-1, IL-8, IL-12,
and TNF a), while sparing expression of IL-10, an anti-
inflammatory cytokine (Fiorucci et al. 2007). The benefit of
ATB-429 over mesalamine is that the former is very poorly
absorbed, and if administered orally in its native form,
mesalamine is very rapidly absorbed in the upper GI tract.
This is undesirable, because IBD primarily affects the
lower GI tract, and high luminal concentrations of mesa-
lamine in the affected area are necessary for beneficial
effects to be produced. The poor absorption of ATB-429
has 2 beneficial outcomes; first, no formulation is needed to
prevent its absorption; second, ATB-429 could treat
inflammation of the mucosa throughout the GI tract when
given orally (Gemici and Wallace 2015). Similarly, intra-
colonic administration of H2S donors reduced TNF-a
mRNA and protein levels in the colon of a colitis rat
model, in association with a significant reduction in the
severity of colitis. An in vitro organ-culture study of
colonic tissue from patients with ulcerative colitis by Bai
et al. (2005), reported that diallyl trisulfide caused a sig-
nificant decrease in TNF-a expression. It is well known
that TNBS can induce chronic inflammation for long
duration with changes in acute inflammatory markers, such
as MPO and interleukins (Szalai et al. 2014). Furthermore,
it was previously addressed that TNBS-induced immuno-
logical inflammatory changes led to hydropsia, necrosis,
erosion and ulceration in colonic tissue as indicated by an
increase in colonic mucosal damage score, adhesions and
colonic weight (Ghatule et al. 2014). Heme oxygenase
(HO) is a cytoprotective/anti-inflammatory enzyme that
exists in two major isoforms: the inducible form (HO-1)
and the constitutive (HO-2) form (Varga et al. 2007);
whereas, the effect of H2S on HO activity and HO-1
expression is still ambiguous. HO-1 catalyzes ferroproto-
porphyrin to generate biliverdin, bilirubin, and carbon
monoxide, and these enzymatic products are in part
responsible for HO-1 action (Zhong et al. 2010). The
protective role of exogenous H2S donor in TNBS- induced
injury in the colon and its possible protective mechanisms
were assessed, focusing on the HO-1 enzyme, and the
obtained results demonstrated herein that the two mole-
cules (H2S and HO) can have a dual interaction, causing an
increase in total HO activity and HO-1 expression and
playing a potent anti-inflammatory protective role against
IBD. According to our knowledge, it is well known that
oxidative stress, hypoxia and inflammation could induce
HO-1 expression in the colon for the purpose of cytopro-
tection against these noxious stimuli, and a study done by
Erbil et al. (2007), on a TNBS colitis model that HO-1 was
overexpressed after HO-1 immunohistochemistry. It was
also suggested by Wang et al. (2001) that TNBS-induced
HO-1 overexpression is presumably due to an increase in
ROS production. The mechanisms by which the up-regu-
lation of the heme- oxygenase system can reduce
inflammatory injury are likely involving the end-products
of the enzymatic reactions (Wang et al. 2001, Pae and
Chung 2009). These heme oxygenase products (biliverdin
and bilirubin) possess anti-oxidant properties that can
reduce lipid peroxidation, and attenuate mesenteric neu-
trophil rolling, adhesion and migration in acute
inflammation (Maines 2005). In our experiments, sul-
fasalazine (SASP) was used as a positive control.
Sulfasalazine, introduced in 1942, is a highly useful pro-
drug, and one of the few available for the treatment of
several types of chronic inflammatory intestinal diseases
and rheumatoid arthritis. Through the action of intestinal
azoreductases, this prodrug releases, in vivo, two pharma-
cologically active substances, sulfapyridine and
5-aminosalicylic acid (5-ASA). 5-ASA is the effective
component in diseases of the colon; however, after oral
administration it undergoes intense absorption in the upper
parts of the gastrointestinal tract, and is not locally effec-
tive on the colon (Davila and Ranganathan 2011).
According to Horva´th et al., 5-ASA treatment could at least
in part mediate its anti-inflammatory effects via upregula-
tion of HO-1 in a TNBS-induced colitis rat model (Horvath
et al. 2008). In addition, carbon monoxide (CO) the
metabolite of HO also has anti-inflammatory properties,
including down-regulation of pro-inflammatory cytokines
and affecting inflammatory cell functions (Otterbein et al.
2000). The activity and expression levels of the H2S-gen-
erating enzymes (CBS and CSE) were also tested in our
experiments, and overall it was obvious that TNBS treat-
ment could decrease the activity and expression of both
enzymes, leading to reduction in the endogenous H2S
generation capacity. For the sake of studying the function
of HO-1; hemin, which is a substrate and inducer of HO-1
and tin protoporphyrin IX (SnPP), as a well-known inhi-
bitor of HO-1 are widely used in experiments (Zhong et al.
2010). Based on this fact, and to confirm that H2S donor-
induced colonoprotection was mediated by HO system, rats
were separately treated with SnPP, and obtained results
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clearly confirmed that the protective effect of H2S was
abolished in the presence of SnPP, indicating that HO acts
as a signal molecule in the H2S-mediated colonoprotection.
Conclusions
In summary, this study provided supportive evidence that
H2S is an important regulator of inflammation, and its
protective effect is mediated through the modulation of the
HO enzyme system in the colon. These findings provide an
important step towards improving the treatments of IBD.
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